Hypertension in psoriasis and lichen planus patients –
A case control study

Dr. Rohit Singla, Dr. Kritika Singla, Dr. Sanjeev Gupta and Dr. Aneet Mahendra

DOI: https://doi.org/10.33545/26649411.2020.v3.i2b.48

Abstract

Background: Psoriasis and lichen planus (LP) both are chronic inflammatory disorders of the skin. The recent data shows increased prevalence of diabetes mellitus and metabolic syndrome (MS) in these patients. MS is described as a risk factor for cardiovascular disorders (CVDs). If there is increased risk of CVDs in such patients, they should be screened for blood pressure when they visit dermatology OPDs. The present study is to find out if there is any need of screening such patients for blood pressure or not.

Objectives: To find out the association of psoriasis and lichen planus with hypertension.

Methods: 60 LP patients, 60 psoriasis patients and 60 healthy individuals were selected for the study and their blood pressure was measured after taking the written informed consent.

Results: 33.3% of the psoriasis patients, 38.3% of LP cases and 20% of controls were found to be hypertensive. The difference was statistically significant in both psoriasis as well as LP cases compared to controls (p<0.05).

Conclusion: Blood pressure was found to be raised in LP and psoriasis patients as compared to controls.

Keywords: Psoriasis, lichen planus, hypertension

Introduction

Psoriasis and LP, both are inflammatory disorders with altered T-cell expression leading to cutaneous and muco-cutaneous lesions respectively [1, 2]. Recent studies show that the immune system, autoimmunity and the inflammatory response of the body play a major role in increasing the blood pressure in the vessels [3]. As, LP and psoriasis, both have immunological aetiology with altered inflammatory response of T-cells, there might be a direct etiological relationship between hypertension and these two cutaneous disorders. Secondly, psoriasis and lichen planus (LP) both are chronic cutaneous disorders having psychological impact on the patients [4]. Stress is one of the causes of exacerbation of these two conditions and also, the appearance of the lesions on exposed parts, pruritus associated with these diseases and their chronic nature become the reason for the stress making it a vicious cycle. This can lead to increased prevalence of hypertension in these patients. Theoretically also, the increased prevalence of HTN in these patients could be due to many reasons -

- Angiotensin II which regulates the vascular tone also stimulates the release of pro-inflammatory cytokines when present in increased levels. In psoriasis patients, elevated plasma renin activity has been reported leading to increased release of angiotensin II [5].

- Endothelin-1 produced by keratinocytes is found in increased amount in both serum and lesional skin of patients with psoriasis as well as LP. The levels also correlate with the severity of the disease. It is a potent vasoconstrictor and may contribute to HTN in such patients [6].

- Oxidative stress, which is present in patients with psoriasis and LP, may play a role in HTN by destructive effects of reactive oxygen species, damaging endothelium-dependent vasodilatation [8, 6].

- Patient already taking treatment for HTN can get lichen planus or lichenoid lesions as side-effect of the anti-hypertensive drugs [7].
Similarly, patients having psoriatic arthritis take medications such as NSAIDs and Cox-2 inhibitors which could contribute to increased blood pressure [8]. However, these confounders had been excluded from this study as the objective was to find the direct association of these conditions with HTN. Psoriasis and LP have been associated with various systemic and metabolic disorders [9, 10]. The recent data shows increased prevalence of metabolic syndrome (MS) in these patients [11, 12]. MS is described as a risk factor for cardiovascular disorders (CVDs) [13]. The expanding epidemiological data suggests that not only MS, but the individual components of MS including diabetes mellitus, obesity, dyslipidemia and hypertension have increased prevalence in these cutaneous disorders [9, 10, 14]. Hypertension is a major risk factor for the development of CVDs and thus, it is an important modifiable cause of premature morbidity and mortality. If there is increased risk of CVDs in such patients, they should be screened for blood pressure when they visit dermatology OPDs.

Materials and Methods
This is a cross sectional study comprised of 60 psoriasis patients, 60 LP patients and 60 age and sex matched controls. This was a hospital based descriptive study. The study population included psoriasis and LP patients with age ranging from 30 years to 60 years attending Out Patient Department of Dermatology Dept. Psoriatic arthritis patients, pregnant women, patients on oral steroids, retinoids, NSAIDs and those who were already taking medications such as Cox 2 inhibitors were excluded from the study. An informed consent was taken from all subjects and clinical data of each patient was recorded on a standard Performa. A detailed history including the occupation, duration of the disease, treatment taken, family history, drug intake and personal history was taken before clinical examination. Study was approved by the ethical committee of the College.

Blood pressure (BP) was recorded for all the patients. BP was recorded after subjects have been lying in supine position for five minutes. Comparisons between patients and controls were performed by chi square analysis for qualitative variables. Odds ratios (ORs) and Confidence Intervals (CIs) were calculated with exact conditional logistic regression. A value of \( P \leq 0.05 \) was considered statistically significant.

Results
46.67% of psoriasis patients belonged to the age group 31-40 years. LP was found more common in 41-50 years’ age group (45%). In control group, 40% belonged to 31-40 years. LP was found more common in 41-50 years similar to other studies [15]. 82% of psoriasis patients presented with plaque type of psoriasis. Majority of the LP patients (72%) were found to have classical type of LP with 34% having mucosal involvement. These findings correlated with other studies [13, 16].

There are many studies which show positive association between these two skin diseases and HTN. As early as in 1949, Lynch FW [17], reported apparent association of LP with hypertension but it could be due to various other factors including the medication. He found the increased prevalence of HTN in LP patients. Kim HN et al. [18] in a cohort study found a statistically significant association of HTN with psoriasis.

However, few studies did not show any statistically significant relationship between hypertension and these inflammatory skin disorders.

Okpala IC et al. [19] neither found any increased prevalence of HTN nor metabolic syndrome in LP patients. Even Christensen et al. [20] and Chattopadhyay A et al. [21] in their studies could not establish any association between LP and HTN. It could have been possible that these studies included the control group patients suffering from other inflammatory disorders of skin or the patients already prone to HTN. In present study, the control group was selected from the hospital workers and relatives visiting with the OPD patients.

Our study revealed a significant association of HTN with LP and psoriasis. As thus, timely screening of such patients is essential. These findings may help us to formulate guidelines for these patients to prevent systemic complications.

Acknowledgements
We would like to give our thanks to the subjects for their participation in this project. We are also grateful to all the staff members and my colleagues in our department for their concern and support our work.

Table 1: Age wise distribution of patients and control group with hypertension

| Age groups | No. of patients | Patients with HTN | Psoriasis | Lichen planus | Control |
|------------|----------------|------------------|-----------|--------------|---------|
| 31-40      | 28             | 8                | 21        | 7            | 24      | 3       |
| 41-50      | 23             | 9                | 27        | 11           | 22      | 7       |
| 51-60      | 9              | 3                | 12        | 5            | 14      | 2       |

Table 2: Percentage of hypertensive patients in each group

| Patients with HTN | Percentage |
|-------------------|------------|
| Psoriasis         | 20         | 33.3%      |
| Lichen planus     | 23         | 38.3%      |
| Control           | 12         | 20%        |
Fig 1: Genital Lichen planus

Fig 2: Lichen planus involving back

References
1. Usatine RP, Tnitigian M. Diagnosis and treatment of lichen planus. Am Fam Physician 2011;84(1):53-60.
2. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J, et al. Association between psoriasis and the metabolic syndrome: A cross-sectional study. Dermatology 2008;216(2):152-5.
3. Crim MT, Yoon SS, Ortiz E, Wall HK, Schober S, Gillespie C, et al. National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes 2012;5(3):343-51.
4. Sampogna F, Picardi A. Association between poorer quality of life and psychiatric morbidity in patients with different Dermatological conditions. Psychosomatic Medicine 2004;66(4):620-24.
5. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 2015;151(2):161-9.
6. Cohen AD, Weitzman D, Dreither J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010;90(1):23-6.
7. Kaomongkolgit R. Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. J Drugs Dermatol 2010;9(1):73-5.
8. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 2010;3(1):32-8.
9. Dreither J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case control study. Br J Dermatol 2009;161(3):626-9.
10. Lodi G, Pelliccano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis 2010;16(7):601-12.
11. Eisen D. The clinical features, malignant potential, and systemic associations of oral Lichen Planus: a study of 723 patients. J Am Acad Dermatol 2002;46(2):207-14.
12. Padhi T, Garima. Metabolic Syndrome and Skin: Psoriasis and Beyond. Indian J Dermatol 2013;58(4):299-305.
13. Ara SA, Mamatha GP, Rao BB. Incidence of diabetes mellitus in patients with lichen planus. International journal of dental clinics 2011;3(1):29-33.
14. Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernández J, Girón-Prieto MS, Gutiérrez-Salmerón MT, Mellado VG, et al. Cardiovascular risk factors in patients with lichen planus. Am J Med 2011;124(6):543-8.
15. Omal PM, Jacob V, Prathap A, Thomas NG. Prevalence of Oral, Skin, and Oral and Skin Lesions of Lichen Planus in Patients Visiting a Dental School in Southern India. Indian J Dermatol 2012;57(2):107-9.
16. Ireddy SG, Udbalkar SG. Epidemiological study of Lichen Planus. Biomed Research 2014;1(2):1-9.
17. Lynch FW. An apparent association of lichen planus with vascular hypertension. J Invest Dermatol 1949;13(1):43-5.
18. Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One 2018;13(8):e0202854.
19. Okpala IC, Akinboro AO, Ezejoifor IO, Onunu AN, Okwaru BU. Metabolic Syndrome and Dyslipidemia among Nigerians with Lichen Planus: A Cross-Sectional Study. Indian J Dermatol 2019;64(4):303-310.
20. Christensen E, Holmstrup P, Wiberg-Jorgensen F, Neumann-Jensen B, Pindborg JJ. Arterial blood pressure in patients with oral lichen planus. J Oral Pathol 1977;6(3):139-42.
21. Chattopadhyay A. Arterial blood pressure and blood glucose levels in oral lichen planus patients in Calcutta (India). Indian J Dent Res 1992;3(3):84-9.